GlassScriptPhysician profile
Daryl J Victor
NPI 1811997323
$61,180.13
in general payments reported to CMS, 2019-2025
62 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,567 · 2020: $2,392 · 2021: $3,448 · 2022: $5,458 · 2023: $11K · 2024: $17K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $14K · Consulting Fee: $460 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,990.00 |
| Food and Beverage | $13,744.94 |
| Consulting Fee | $460.00 |
| Education | $119.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35,068.23 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $2,671.05 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Acadia Pharmaceuticals INC | $2,550.94 | 2019-2025 | Nuplazid |
| Abbvie INC. | $1,833.52 | 2021-2025 | Botox, Duopa, Ubrelvy |
| Abbott Laboratories | $1,824.04 | 2019-2025 | Infinity |
| Eisai INC. | $1,419.36 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,363.11 | 2019-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $1,078.08 | 2019-2025 | Crexont, Rytary, Ongentys |
| Mdd US Operations, LLC | $730.45 | 2019-2021 | |
| Emd Serono, INC. | $690.33 | 2019-2024 | Mavenclad |
| Amgen INC. | $663.19 | 2019-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $660.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.37 | 2019-2022 | |
| Kyowa Kirin, INC. | $604.33 | 2020-2024 | Nourianz |
| Sk Life Science, INC. | $594.00 | 2021-2025 | Xcopri |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Victor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.